THE DEAL, AT A GLANCE
From the announcementBionyra
01Who is involvedBacked by TrueLab BiopharmaceuticalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedBionyra raised $165M Series A, announced 2026-06-22From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersBionyra is a newly launched inflammation antibody company using a $165M Series A to develop licensed assets for immune-mediated inflammatory diseases.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Bionyra · Financing Record
Explore source-linked visual explanations for Bionyra. Unsupported claims are withheld while source review continues.
Record 6536 · Recorded date: 2026-06-22
Explore company records →